NATEGLINIDE Side Effects

6994616-6 | Diabetes Mellitus Inadequate Control, Dyspnoea, Heart Rate Increased, Pruritus
on Sep 16, 2010 Female patient from UNITED STATES , weighting 163.4 lb, was diagnosed with diabetes mellitus and was treated with Nateglinide (View Usage). Patient experienced the following unwanted or unexpected effects: diabetes mellitus inadequate control, dyspnoea, heart rate increased, pruritus. Nateglinide dosage: 60mg 3 Times Daily Medco. During the same period patient was treated with JANUVIA (View Januvia Review and Januvia Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ).

6969535-1 | Dizziness, Nausea, No Therapeutic Response
Patient was taking Nateglinide (View Usage). Patient had the following side effects: dizziness (What is dizziness?), nausea (What is nausea?), no therapeutic response on Sep 07, 2010 from UNITED STATES Additional patient health information: Female patient , 60 years of age, weighting 227.0 lb, was diagnosed with diabetes mellitus and. Nateglinide dosage: One Po Tid.

6830631-0 | Abdominal Pain Upper, Diarrhoea, Product Substitution Issue
Adverse event was reported on Jul 09, 2010 by a Male patient taking Nateglinide (View Usage) (Dosage: 120 Mgs Tid Oral) was diagnosed with diabetes mellitus and. Location: UNITED STATES , 69 years of age, weighting 299.0 lb, After Nateglinide was administered, patient had the following side effects: abdominal pain upper, diarrhoea, product substitution issue. During the same period patient was treated with METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ), LANTUS (View Lantus Review and Lantus Label ), METFORMIN HCL (METFORMIN HCL) (View Metformin Hcl (metformin Hcl) Review and Metformin Hcl (metformin Hcl) Label ), CLONIDINE HCL (CLONIDINE HCL) (View Clonidine Hcl (clonidine Hcl) Review and Clonidine Hcl (clonidine Hcl) Label ), FISH OIL CAPS (OMEGA 3 FATTY ACIDS CAPS) (View Fish Oil Caps (omega-3 Fatty Acids Caps) Review and Fish Oil Caps (omega-3 Fatty Acids Caps) Label ), ALPRAZOLAM (View Alprazolam Review and Alprazolam Label ).

6748517-9 | Dysgeusia, Oral Discomfort, Product Quality Issue, Product Substitution Issue
on May 27, 2010 Male patient from UNITED STATES , weighting 250.0 lb, was diagnosed with type 2 diabetes mellitus and was treated with Nateglinide (View Usage). Patient experienced the following unwanted or unexpected effects: dysgeusia, oral discomfort, product quality issue, product substitution issue. Nateglinide dosage: 120 Mg Daily Po About 4 Weeks.


6633180-8 | Altered State Of Consciousness, Anaemia, Dehydration, Diabetic Neuropathy, Diarrhoea, Fatigue, Hepatic Function Abnormal, Hypoaesthesia, Hypoglycaemia
on Mar 05, 2010 Male patient from JAPAN , 50 years of age, weighting 160.9 lb, was diagnosed with diabetes mellitus and was treated with Nateglinide (View Usage). Patient had the following side effects: altered state of consciousness, anaemia, dehydration, diabetic neuropathy, diarrhoea, fatigue, hepatic function abnormal, hypoaesthesia, hypoglycaemia. Nateglinide dosage: . During the same period patient was treated with INSULIN (View Insulin Review and Insulin Label ), LOSARTAN POTASSIUM (50 Mg, Per Day) (View Losartan Potassium Review and Losartan Potassium Label ), VERAPAMIL HCL (80 Mg, Per Day) (View Verapamil Hcl Review and Verapamil Hcl Label ), CILOSTAZOL (200 Mg, Per Day) (View Cilostazol Review and Cilostazol Label ), ALLOPURINOL (100 Mg, Per Day) (View Allopurinol Review and Allopurinol Label ), RANITIDINE HYDROCHLORIDE (150 Mg, Per Day) (View Ranitidine Hydrochloride Review and Ranitidine Hydrochloride Label ), THIAMAZOLE (2.5 Mg, Per Day) (View Thiamazole Review and Thiamazole Label ), BISOPROLOL FUMARATE (5 Mg, Per Day) (View Bisoprolol Fumarate Review and Bisoprolol Fumarate Label ). Patient was hospitalized.

6599211-9 | Altered State Of Consciousness, Dehydration, Fatigue, Hypoglycaemia, Hypoglycaemic Coma, Hypophagia, Malaise, Renal Impairment
Patient was taking Nateglinide (View Usage). After Nateglinide was administered, patient had the following side effects: altered state of consciousness, dehydration, fatigue, hypoglycaemia, hypoglycaemic coma, hypophagia, malaise, renal impairment on Feb 12, 2010 from JAPAN Additional patient health information: Male patient , 50 years of age, was diagnosed with diabetes mellitus and. Nateglinide dosage: . During the same period patient was treated with INSULIN (View Insulin Review and Insulin Label ). Patient was hospitalized.

6589140-9 | Altered State Of Consciousness, Dehydration, Fatigue, Hypoglycaemia, Hypoglycaemic Coma, Hypophagia, Malaise, Renal Impairment
Adverse event was reported on Feb 12, 2010 by a Male patient taking Nateglinide (View Usage) (Dosage: ) was diagnosed with diabetes mellitus and. Location: JAPAN , 50 years of age, Patient experienced the following unwanted or unexpected effects: altered state of consciousness, dehydration, fatigue, hypoglycaemia, hypoglycaemic coma, hypophagia, malaise, renal impairment. During the same period patient was treated with INSULIN (View Insulin Review and Insulin Label ). Patient was hospitalized.

6558299-1 | Blood Glucose Increased, Cough, Dizziness, Fall, Gait Disturbance, Increased Upper Airway Secretion, Nausea, Product Substitution Issue
on Jan 28, 2010 Female patient from UNITED STATES , 81 years of age, weighting 185.0 lb, was diagnosed with type 2 diabetes mellitus and was treated with Nateglinide (View Usage). Patient had the following side effects: blood glucose increased, cough, dizziness (What is dizziness?), fall (What is fall?), gait disturbance, increased upper airway secretion, nausea (What is nausea?), product substitution issue. Nateglinide dosage: 3 Times A Day Mouth. Patient was hospitalized.

5855988-9 | Diarrhoea, Hyperhidrosis, Lethargy
on Aug 11, 2008 Male patient from UNITED KINGDOM , 73 years of age, weighting 262.4 lb, was diagnosed with hypertension, benign prostatic hyperplasia and was treated with Nateglinide (View Usage). After Nateglinide was administered, patient had the following side effects: diarrhoea, hyperhidrosis, lethargy. Nateglinide dosage: 60 Mg/day. During the same period patient was treated with BENDROFLUAZIDE (2.5 Mg/day) (View Bendrofluazide Review and Bendrofluazide Label ), DOXAZOSIN MESYLATE (8 Mg/day) (View Doxazosin Mesylate Review and Doxazosin Mesylate Label ), LISINOPRIL (30 Mg/day) (View Lisinopril Review and Lisinopril Label ), PROSCAR (5 Mg/day) (View Proscar Review and Proscar Label ).

5727195-1 | Renal Failure Acute
Patient was taking Nateglinide (View Usage). Patient experienced the following unwanted or unexpected effects: renal failure acute on May 02, 2008 from CZECH REPUBLIC Additional patient health information: Female patient , 64 years of age, weighting 209.4 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and. Nateglinide dosage: 60 Mg. Patient was hospitalized.

5726012-3 | Renal Failure Acute
Adverse event was reported on Apr 23, 2008 by a Female patient taking Nateglinide (View Usage) (Dosage: 60 Mg) was diagnosed with glucose tolerance impaired, cardiovascular disorder and. Location: CZECH REPUBLIC , 64 years of age, weighting 209.4 lb, Patient had the following side effects: renal failure acute. Patient was hospitalized.

5723314-1 | Arrhythmia, Arteriosclerosis, Cardiac Ablation, Disease Progression, Dizziness, Extrasystoles, Hypertension, Implantable Defibrillator Insertion, Palpitations
on Apr 25, 2008 Male patient from UNITED STATES , 67 years of age, weighting 267.6 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder, hypertension and was treated with Nateglinide (View Usage). After Nateglinide was administered, patient had the following side effects: arrhythmia (What is arrhythmia?), arteriosclerosis, cardiac ablation, disease progression, dizziness (What is dizziness?), extrasystoles, hypertension, implantable defibrillator insertion, palpitations. Nateglinide dosage: Level 1. During the same period patient was treated with METOPROLOL TARTRATE (150 Mg, Bid) (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), LASIX (View Lasix Review and Lasix Label ). Patient was hospitalized.

5718977-0 | Asthenia, Cardiac Failure Congestive, Chest Pain, Concomitant Disease Progression, Dizziness, Dyspnoea Exertional, Goitre, Headache
on Apr 17, 2008 Female patient from RUSSIAN FEDERATION , 65 years of age, weighting 156.5 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with Nateglinide (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, cardiac failure congestive, chest pain (What is chest pain?), concomitant disease progression, dizziness (What is dizziness?), dyspnoea exertional, goitre, headache (What is headache?). Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5712412-4 | Acute Coronary Syndrome, Chest Pain, Dyspnoea
Patient was taking Nateglinide (View Usage). Patient had the following side effects: acute coronary syndrome, chest pain (What is chest pain?), dyspnoea on Apr 11, 2008 from UNITED STATES Additional patient health information: Male patient , 72 years of age, weighting 196.2 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and. Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5699656-5 | Abdominal Pain Upper, Gastritis, Gastritis Erosive, Intestinal Operation, Laparotomy, Non-hodgkin's Lymphoma Stage Iv, Shock, Small Intestinal Haemorrhage, Vomiting
Adverse event was reported on Apr 03, 2008 by a Male patient taking Nateglinide (View Usage) (Dosage: Level 1) was diagnosed with glucose tolerance impaired, cardiovascular disorder and. Location: CHINA , 69 years of age, weighting 163.1 lb, After Nateglinide was administered, patient had the following side effects: abdominal pain upper, gastritis, gastritis erosive, intestinal operation, laparotomy, non-hodgkin's lymphoma stage iv, shock, small intestinal haemorrhage, vomiting. During the same period patient was treated with VALSARTAN (80 Mg, Qd) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5669714-X | Asthenia, Blood Potassium Increased, Blood Sodium Decreased, Electrolyte Imbalance, Gait Disturbance, Hyponatraemia, Polyuria, Vomiting
on Mar 05, 2008 Male patient from SPAIN , 88 years of age, weighting 130.1 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with Nateglinide (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, blood potassium increased, blood sodium decreased, electrolyte imbalance, gait disturbance, hyponatraemia, polyuria, vomiting. Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5662498-0 | Acute Coronary Syndrome, Acute Myocardial Infarction, Angina Pectoris, Angina Unstable, Arterial Haemorrhage, Chest Pain, Coronary Angioplasty, Coronary Arterial Stent Insertion, Coronary Artery Disease
on Mar 04, 2008 Female patient from UNITED STATES , 53 years of age, weighting 280.0 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with Nateglinide (View Usage). Patient had the following side effects: acute coronary syndrome, acute myocardial infarction, angina pectoris, angina unstable, arterial haemorrhage, chest pain (What is chest pain?), coronary angioplasty, coronary arterial stent insertion, coronary artery disease (What is coronary artery disease?). Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5633572-X | Cough, Pneumonia, Productive Cough, Renal Failure Chronic, Renal Impairment
Patient was taking Nateglinide (View Usage). After Nateglinide was administered, patient had the following side effects: cough, pneumonia (What is pneumonia?), productive cough, renal failure chronic, renal impairment on Feb 12, 2008 from CHINA Additional patient health information: Male patient , 73 years of age, weighting 135.4 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and. Nateglinide dosage: Level 2. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5624228-8 | Abdominal Pain, Arrhythmia, Atrioventricular Block, Disease Progression, Dyspnoea, Electrocardiogram Qt Prolonged, Ventricular Fibrillation, Ventricular Tachycardia
Adverse event was reported on Feb 08, 2008 by a Female patient taking Nateglinide (View Usage) (Dosage: 60 Mg, Unk) was diagnosed with glucose tolerance impaired, arrhythmia (What is arrhythmia?), hypertension, dyslipidaemia and. Location: BRAZIL , 79 years of age, weighting 154.3 lb, Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), arrhythmia (What is arrhythmia?), atrioventricular block, disease progression, dyspnoea, electrocardiogram qt prolonged, ventricular fibrillation, ventricular tachycardia. During the same period patient was treated with CARVEDILOL (View Carvedilol Review and Carvedilol Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), CAPTOPRIL (View Captopril Review and Captopril Label ), ACETYLSALICYLATE (View Acetylsalicylate Review and Acetylsalicylate Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ). Patient was hospitalized.

5624227-6 | Abdominal Pain, Arrhythmia, Atrioventricular Block, Disease Progression, Dyspnoea, Electrocardiogram Qt Prolonged, Ventricular Fibrillation, Ventricular Tachycardia
on Feb 08, 2008 Female patient from BRAZIL , 79 years of age, weighting 154.3 lb, was diagnosed with glucose tolerance impaired, arrhythmia (What is arrhythmia?), hypertension, dyslipidaemia and was treated with Nateglinide (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), arrhythmia (What is arrhythmia?), atrioventricular block, disease progression, dyspnoea, electrocardiogram qt prolonged, ventricular fibrillation, ventricular tachycardia. Nateglinide dosage: 60 Mg, Unk. During the same period patient was treated with CARVEDILOL (View Carvedilol Review and Carvedilol Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), CAPTOPRIL (View Captopril Review and Captopril Label ), ACETYLSALICYLATE (View Acetylsalicylate Review and Acetylsalicylate Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ). Patient was hospitalized.

5621715-3 | Abdominal Pain, Arrhythmia, Disease Progression, Dyspnoea, Ventricular Fibrillation, Ventricular Tachycardia
on Feb 01, 2008 Female patient from BRAZIL , 79 years of age, weighting 154.3 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder, arrhythmia (What is arrhythmia?), hypertension and was treated with Nateglinide (View Usage). After Nateglinide was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), arrhythmia (What is arrhythmia?), disease progression, dyspnoea, ventricular fibrillation, ventricular tachycardia. Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ), CARVEDILOL (View Carvedilol Review and Carvedilol Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), CAPTOPRIL (View Captopril Review and Captopril Label ), ACETYLSALICYLATE (View Acetylsalicylate Review and Acetylsalicylate Label ). Patient was hospitalized.

5619804-2 | Abdominal Pain Upper, Gastritis, Gastritis Erosive, Intestinal Operation, Laparotomy, Metastases To Lung, Non-hodgkin's Lymphoma, Shock, Small Intestinal Haemorrhage
Patient was taking Nateglinide (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain upper, gastritis, gastritis erosive, intestinal operation, laparotomy, metastases to lung, non-hodgkin's lymphoma, shock, small intestinal haemorrhage on Feb 01, 2008 from CHINA Additional patient health information: Male patient , 69 years of age, weighting 163.1 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and. Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (80 Mg, Qd) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5619072-1 | Cough, Pneumonia, Productive Cough, Renal Failure Chronic
Adverse event was reported on Jan 31, 2008 by a Male patient taking Nateglinide (View Usage) (Dosage: Level 2) was diagnosed with glucose tolerance impaired, cardiovascular disorder and. Location: CHINA , 73 years of age, weighting 135.4 lb, Patient had the following side effects: cough, pneumonia (What is pneumonia?), productive cough, renal failure chronic. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5618945-3 | Cough, Pneumonia, Productive Cough, Renal Failure Chronic
on Jan 31, 2008 Male patient from CHINA , 73 years of age, weighting 135.4 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with Nateglinide (View Usage). After Nateglinide was administered, patient had the following side effects: cough, pneumonia (What is pneumonia?), productive cough, renal failure chronic. Nateglinide dosage: Level 2. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5616700-1 | Chest Pain, Coronary Artery Disease, Coronary Artery Stenosis, Goitre, Loss Of Consciousness, Myocardial Ischaemia, Palpitations, Sensation Of Pressure
on Jan 30, 2008 Female patient from IRELAND , 77 years of age, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with Nateglinide (View Usage). Patient experienced the following unwanted or unexpected effects: chest pain (What is chest pain?), coronary artery disease (What is coronary artery disease?), coronary artery stenosis, goitre, loss of consciousness, myocardial ischaemia, palpitations, sensation of pressure. Nateglinide dosage: . During the same period patient was treated with VALSARTAN (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5611241-X | Blood Sodium Decreased, Electrolyte Imbalance
Patient was taking Nateglinide (View Usage). Patient had the following side effects: blood sodium decreased, electrolyte imbalance on Jan 23, 2008 from SPAIN Additional patient health information: Male patient , 88 years of age, weighting 130.1 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and. Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5602160-3 | Blood Sodium Decreased, Electrolyte Imbalance
Adverse event was reported on Jan 16, 2008 by a Male patient taking Nateglinide (View Usage) (Dosage: Level 1) was diagnosed with glucose tolerance impaired, cardiovascular disorder and. Location: SPAIN , 88 years of age, weighting 130.1 lb, After Nateglinide was administered, patient had the following side effects: blood sodium decreased, electrolyte imbalance. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5599564-4 | Asthenia, Coordination Abnormal, Diplopia, Dizziness, Guillain-barre Syndrome, Hyponatraemia, Hypotension, Hypovolaemia, Liver Function Test Abnormal
on Jan 14, 2008 Female patient from UNITED STATES , 77 years of age, weighting 147.7 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder, hypertension, hyperlipidaemia and was treated with Nateglinide (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, coordination abnormal, diplopia, dizziness (What is dizziness?), guillain-barre syndrome (What is guillain-barre syndrome?), hyponatraemia, hypotension, hypovolaemia, liver function test abnormal. Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (Level 2) (View Valsartan Review and Valsartan Label ), NORVASC (10 Mg, Qd) (View Norvasc Review and Norvasc Label ), LIPITOR (40 Mg, Qd) (View Lipitor Review and Lipitor Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), LASIX (View Lasix Review and Lasix Label ). Patient was hospitalized.

5597134-5 | Renal Failure Chronic
on Jan 11, 2008 Male patient from UNITED KINGDOM , 70 years of age, weighting 148.8 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with Nateglinide (View Usage). Patient had the following side effects: renal failure chronic. Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (No Treatment) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5595578-9 | Electrolyte Imbalance
Patient was taking Nateglinide (View Usage). After Nateglinide was administered, patient had the following side effects: electrolyte imbalance on Jan 09, 2008 from Additional patient health information: Male patient , 88 years of age, weighting 130.1 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and. Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5573338-2 | Blood Alkaline Phosphatase Increased
Adverse event was reported on Dec 20, 2007 by a Male patient taking Nateglinide (View Usage) (Dosage: Level 1) was diagnosed with glucose tolerance impaired, cardiovascular disorder and. Location: UNITED KINGDOM , 74 years of age, weighting 182.3 lb, Patient experienced the following unwanted or unexpected effects: blood alkaline phosphatase increased. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ).

5572846-8 | Renal Failure Chronic
on Dec 19, 2007 Male patient from UNITED KINGDOM , 70 years of age, weighting 148.8 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with Nateglinide (View Usage). Patient had the following side effects: renal failure chronic. Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (No Treatment) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5532768-5 | Abdominal Pain Upper, Anorexia, Ascites, Gastric Cancer, Gastric Operation, Gastric Ulcer, Gastrooesophageal Reflux Disease, Ileus, Nausea
on Nov 29, 2007 Male patient from JAPAN , 74 years of age, was treated with Nateglinide (View Usage). After Nateglinide was administered, patient had the following side effects: abdominal pain upper, anorexia, ascites, gastric cancer, gastric operation, gastric ulcer, gastrooesophageal reflux disease, ileus, nausea (What is nausea?). Nateglinide dosage: 180 Mg/day. During the same period patient was treated with ACTOS (30 Mg/day) (View Actos Review and Actos Label ), TAKEPRON (View Takepron Review and Takepron Label ), KINEDAK (View Kinedak Review and Kinedak Label ), AMARYL (View Amaryl Review and Amaryl Label ), TS 1 (120 Mg, Bid) (View Ts 1 Review and Ts 1 Label ). Patient was hospitalized.

5524510-9 | Abdominal Pain Upper, Gastric Cancer, Gastric Operation, Gastric Ulcer, Gastrooesophageal Reflux Disease
Patient was taking Nateglinide (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain upper, gastric cancer, gastric operation, gastric ulcer, gastrooesophageal reflux disease on Nov 20, 2007 from JAPAN Additional patient health information: Male patient , 74 years of age, . Nateglinide dosage: 180 Mg/day. During the same period patient was treated with ACTOS (30 Mg/day) (View Actos Review and Actos Label ), TAKEPRON (View Takepron Review and Takepron Label ), KINEDAK (View Kinedak Review and Kinedak Label ), AMARYL (View Amaryl Review and Amaryl Label ). Patient was hospitalized.

5521703-1 | Abdominal Pain Upper, Gastric Cancer, Gastric Operation, Gastric Ulcer, Gastrooesophageal Reflux Disease
Adverse event was reported on Nov 16, 2007 by a Male patient taking Nateglinide (View Usage) (Dosage: 180 Mg/day) . Location: JAPAN , 74 years of age, Patient had the following side effects: abdominal pain upper, gastric cancer, gastric operation, gastric ulcer, gastrooesophageal reflux disease. During the same period patient was treated with ACTOS (30 Mg/day) (View Actos Review and Actos Label ), TAKEPRON (View Takepron Review and Takepron Label ), KINEDAK (View Kinedak Review and Kinedak Label ), AMARYL (View Amaryl Review and Amaryl Label ). Patient was hospitalized.

5502585-0 | Arrhythmia, Cardiac Ablation, Disease Progression, Dizziness, Extrasystoles, Implantable Defibrillator Insertion, Palpitations, Pneumonia
on Oct 24, 2007 Male patient from UNITED STATES , 67 years of age, weighting 267.6 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder, hypertension and was treated with Nateglinide (View Usage). After Nateglinide was administered, patient had the following side effects: arrhythmia (What is arrhythmia?), cardiac ablation, disease progression, dizziness (What is dizziness?), extrasystoles, implantable defibrillator insertion, palpitations, pneumonia (What is pneumonia?). Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ), METOPROLOL (150 Mg, Bid) (View Metoprolol Review and Metoprolol Label ), LASIX (View Lasix Review and Lasix Label ). Patient was hospitalized.

5483274-8 | Angina Pectoris, Chest Discomfort, Diarrhoea, Gouty Arthritis, Reflux Oesophagitis
on Oct 03, 2007 Male patient from MALAYSIA , 67 years of age, weighting 174.2 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with Nateglinide (View Usage). Patient experienced the following unwanted or unexpected effects: angina pectoris, chest discomfort, diarrhoea, gouty arthritis, reflux oesophagitis. Nateglinide dosage: 60 Mg, Unk. During the same period patient was treated with VALSARTAN (160 Mg) (View Valsartan Review and Valsartan Label ), TICLID (250 Mg / Day) (View Ticlid Review and Ticlid Label ), PLAVIX (75 Mg / Day) (View Plavix Review and Plavix Label ), BETALOC (50 Mg / Day) (View Betaloc Review and Betaloc Label ), LOVASTATIN (40 Mg / Day) (View Lovastatin Review and Lovastatin Label ), VASTAREL (120 Mg / Day) (View Vastarel Review and Vastarel Label ), ISORDIL (10 Mg / Day) (View Isordil Review and Isordil Label ), ISOSORBIDE MONONITRATE (View Isosorbide Mononitrate Review and Isosorbide Mononitrate Label ). Patient was hospitalized.

5481207-1 | Lipoma, Lipoma Excision, Lithotripsy, Obstructive Uropathy
Patient was taking Nateglinide (View Usage). Patient had the following side effects: lipoma, lipoma excision, lithotripsy, obstructive uropathy on Oct 05, 2007 from UNITED STATES Additional patient health information: Female patient , 85 years of age, was diagnosed with glucose tolerance impaired, cardiovascular disorder and. Nateglinide dosage: . During the same period patient was treated with DIOVAN (View Diovan Review and Diovan Label ). Patient was hospitalized.

5479210-0 | Lipoma, Lipoma Excision, Lithotripsy, Obstructive Uropathy
Adverse event was reported on Sep 28, 2007 by a Female patient taking Nateglinide (View Usage) (Dosage: ) was diagnosed with glucose tolerance impaired, cardiovascular disorder and. Location: UNITED STATES , 85 years of age, After Nateglinide was administered, patient had the following side effects: lipoma, lipoma excision, lithotripsy, obstructive uropathy. During the same period patient was treated with DIOVAN (View Diovan Review and Diovan Label ). Patient was hospitalized.

5479146-5 | Abdominal Pain, Blood Urea Increased, Diarrhoea, Dizziness, Fall, Gastroenteritis, Neck Pain, Presyncope, Urinary Tract Infection
on Sep 28, 2007 Male patient from UNITED STATES , 76 years of age, weighting 190.3 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with Nateglinide (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), blood urea increased, diarrhoea, dizziness (What is dizziness?), fall (What is fall?), gastroenteritis (What is gastroenteritis?), neck pain, presyncope, urinary tract infection (What is urinary tract infection?). Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ), COUMADIN (View Coumadin Review and Coumadin Label ), CLONIDINE (View Clonidine Review and Clonidine Label ), METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ), TOPROL XL (View Toprol-xl Review and Toprol-xl Label ), CRESTOR (View Crestor Review and Crestor Label ). Patient was hospitalized.

5475414-1 | Angina Pectoris, Chest Discomfort, Diarrhoea, Gouty Arthritis, Reflux Oesophagitis
on Sep 20, 2007 Male patient from MALAYSIA , 67 years of age, weighting 174.2 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with Nateglinide (View Usage). Patient had the following side effects: angina pectoris, chest discomfort, diarrhoea, gouty arthritis, reflux oesophagitis. Nateglinide dosage: 60 Mg, Unk. During the same period patient was treated with VALSARTAN (160 Mg) (View Valsartan Review and Valsartan Label ), TICLID (250 Mg / Day) (View Ticlid Review and Ticlid Label ), PLAVIX (75 Mg / Day) (View Plavix Review and Plavix Label ), BETALOC (50 Mg / Day) (View Betaloc Review and Betaloc Label ), LOVASTATIN (40 Mg / Day) (View Lovastatin Review and Lovastatin Label ), VASTAREL (120 Mg / Day) (View Vastarel Review and Vastarel Label ), ISORDIL (10 Mg / Day) (View Isordil Review and Isordil Label ), ISOSORBIDE MONONITRATE (View Isosorbide Mononitrate Review and Isosorbide Mononitrate Label ). Patient was hospitalized.

5475398-6 | Arrhythmia, Cardiac Ablation, Disease Progression, Dizziness, Extrasystoles, Implantable Defibrillator Insertion, Palpitations, Presyncope, Sinus Bradycardia
Patient was taking Nateglinide (View Usage). After Nateglinide was administered, patient had the following side effects: arrhythmia (What is arrhythmia?), cardiac ablation, disease progression, dizziness (What is dizziness?), extrasystoles, implantable defibrillator insertion, palpitations, presyncope, sinus bradycardia on Sep 24, 2007 from UNITED STATES Additional patient health information: Male patient , 67 years of age, weighting 267.6 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder, hypertension and. Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ), METOPROLOL (150 Mg, Bid) (View Metoprolol Review and Metoprolol Label ), LASIX (View Lasix Review and Lasix Label ). Patient was hospitalized.

5470575-2 | Arrhythmia, Disease Progression, Dizziness, Extrasystoles, Implantable Defibrillator Insertion, Palpitations, Presyncope, Sinus Bradycardia, Ventricular Extrasystoles
Adverse event was reported on Sep 18, 2007 by a Male patient taking Nateglinide (View Usage) (Dosage: Level 1) was diagnosed with glucose tolerance impaired, cardiovascular disorder, hypertension and. Location: UNITED STATES , 67 years of age, weighting 267.6 lb, Patient experienced the following unwanted or unexpected effects: arrhythmia (What is arrhythmia?), disease progression, dizziness (What is dizziness?), extrasystoles, implantable defibrillator insertion, palpitations, presyncope, sinus bradycardia, ventricular extrasystoles. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ), METOPROLOL SUCCINATE (150 Mg, Bid) (View Metoprolol Succinate Review and Metoprolol Succinate Label ), LASIX (View Lasix Review and Lasix Label ). Patient was hospitalized.

5453666-1 | Abdominal Pain, Nephrolithiasis, Renal Colic, Ureteral Stent Insertion
on Sep 11, 2007 Male patient from UNITED KINGDOM , 68 years of age, weighting 196.2 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with Nateglinide (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), nephrolithiasis, renal colic, ureteral stent insertion. Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5450857-0 | Abdominal Pain, Nephrolithiasis, Ureteral Stent Insertion
on Sep 04, 2007 Male patient from UNITED KINGDOM , 68 years of age, weighting 196.2 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder and was treated with Nateglinide (View Usage). After Nateglinide was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), nephrolithiasis, ureteral stent insertion. Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

5445885-5 | Altered State Of Consciousness, Bladder Irrigation, Blood Albumin Decreased, Blood Creatinine Decreased, Blood Potassium Decreased, Blood Sodium Decreased, Body Mass Index Decreased, Decreased Appetite, Diarrhoea
Patient was taking Nateglinide (View Usage). Patient experienced the following unwanted or unexpected effects: altered state of consciousness, bladder irrigation, blood albumin decreased, blood creatinine decreased, blood potassium decreased, blood sodium decreased, body mass index decreased, decreased appetite, diarrhoea on Aug 30, 2007 from JAPAN Additional patient health information: Male patient , 61 years of age, was diagnosed with diabetes mellitus and. Nateglinide dosage: 270 Mg Qd. During the same period patient was treated with GLUCOBAY (View Glucobay Review and Glucobay Label ), MELBIN (500 Mg, Unk) (View Melbin Review and Melbin Label ), FAMOTIDINE (20 Mg, Unk) (View Famotidine Review and Famotidine Label ), ALDACTONE (25 Mg, Unk) (View Aldactone Review and Aldactone Label ), LASIX (20 Mg, Unk) (View Lasix Review and Lasix Label ), METHYCOBAL (1 Mg, Unk) (View Methycobal Review and Methycobal Label ). Patient was hospitalized.

5432981-1 | Cervical Vertebral Fracture, Contusion, Fall, Hypotension, Loss Of Consciousness, Skin Laceration, Syncope
Adverse event was reported on Aug 22, 2007 by a Male patient taking Nateglinide (View Usage) (Dosage: Level 1) was diagnosed with glucose tolerance impaired, cardiovascular disorder, hypertension and. Location: UNITED STATES , 74 years of age, weighting 227.1 lb, Patient had the following side effects: cervical vertebral fracture, contusion, fall (What is fall?), hypotension, loss of consciousness, skin laceration, syncope. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ), FELODIPINE (10 Mg A.m) (View Felodipine Review and Felodipine Label ). Patient was hospitalized.

5419071-9 | Altered State Of Consciousness, Blood Albumin Decreased, Blood Pressure Decreased, Body Mass Index Decreased, Body Temperature Decreased, Decreased Appetite, Diarrhoea, Electrocardiogram Abnormal, Glycosylated Haemoglobin Increased
on Aug 10, 2007 Male patient from JAPAN , 61 years of age, was diagnosed with diabetes mellitus and was treated with Nateglinide (View Usage). After Nateglinide was administered, patient had the following side effects: altered state of consciousness, blood albumin decreased, blood pressure decreased, body mass index decreased, body temperature decreased, decreased appetite, diarrhoea, electrocardiogram abnormal, glycosylated haemoglobin increased. Nateglinide dosage: 270 Mg, Unk. Patient was hospitalized.

5417782-2 | Dizziness, Loss Of Consciousness, Weight Decreased
on Aug 09, 2007 Female patient from UNITED STATES , 74 years of age, weighting 244.5 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder, hypertension and was treated with Nateglinide (View Usage). Patient experienced the following unwanted or unexpected effects: dizziness (What is dizziness?), loss of consciousness, weight decreased. Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ), ATENOLOL (25 Mg, Qd) (View Atenolol Review and Atenolol Label ). Patient was hospitalized.

5417750-0 | Dizziness, Loss Of Consciousness, Weight Decreased
Patient was taking Nateglinide (View Usage). Patient had the following side effects: dizziness (What is dizziness?), loss of consciousness, weight decreased on Aug 09, 2007 from UNITED STATES Additional patient health information: Female patient , 74 years of age, weighting 244.5 lb, was diagnosed with glucose tolerance impaired, cardiovascular disorder, hypertension and. Nateglinide dosage: Level 1. During the same period patient was treated with VALSARTAN (Level 1) (View Valsartan Review and Valsartan Label ), ATENOLOL (25 Mg, Qd) (View Atenolol Review and Atenolol Label ). Patient was hospitalized.